SCL Science: Revenue Surges on Expansion, but Debt Ratio Soars to 240% and Net Loss Widens
Consolidated revenue: KRW 22.0 billion (+365% YoY); Operating loss: KRW 3.4 billion (improved from KRW 3.7 billion); Net loss: KRW 4.1 billion (widened from KRW 3.7 billion)
Total assets: KRW 79.9 billion; Total liabilities: KRW 56.4 billion; Debt ratio: 240% (up from 55%); Current ratio: 95% (down from 158%)
No dividends or share buybacks/cancellations; Accumulated deficit: KRW 43.4 billion
Major changes in 2025: Comprehensive stock exchange with SCL Healthcare, acquisition of Yeongnam/Honam bio-logistics businesses, acquisition of Neogen Logic stake